Hedge Fund Seeks Higher Price For Qiagen As COVID-19 Boosts Sales

Hedge fund Davidson Kempner advised Qiagen to ask for a higher acquisition price from Thermo Fisher Sciences as COVID-19 has increased demand for diagnostic products.

Coronavirus stocks

More from Deals

More from Business